A phase 1/2 study (NCT01752920) of another pan-FGFR inhibitor, ARQ087, included one ACC patient with FGFR1 gene amplification who experienced disease stabilization for 3.5 years with a maximum tumor reduction of 20% post-treatment [80]. This evidence concerns the gene FGFR1 and neoplasm.